Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• Adults aged 18 and older
• Diagnosed with AF before age 60
• Scheduled for catheter-based AF ablation (de-novo or repeat)
• Able to provide written, informed consent
• P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control.
Locations
United States
Tennessee
Vanderbilt University Medical Center
RECRUITING
Nashville
Contact Information
Primary
Dakota D Grauherr, RN
dakota.grauherr@vumc.org
615-714-8674
Backup
Diane M Crawford, RN
diane.m.crawford@vumc.org
615-981-2054
Time Frame
Start Date: 2023-12-13
Estimated Completion Date: 2027-01-01
Participants
Target number of participants: 200
Treatments
Pathogenic variant in TTN
50 patients with a pathogenic variant in TTN
Pathogenic variant in other cardiomyopathy genes
50 patients with a pathogenic variant in other cardiomyopathy genes
Genotype-negative controls
100 genotype-negative controls
Related Therapeutic Areas
Sponsors
Leads: Vanderbilt University Medical Center